Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 20.9% year on year to $1.27 billion. On the other hand, the company’s full-year revenue guidance of $4.86 billion at the midpoint came in 12.9% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 35.1% above analysts’ consensus estimates.

Is now the time to buy INCY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hematology, oncology, and immunology. Management cited successful execution in advancing late-stage pipeline programs, as well as increased prescription volume in key brands like Jakafi and Opzelura. CEO William Meury pointed to the company’s strategic transition beyond its cornerstone product, emphasizing, “We view '26 as a year of strategic progress as we transition Incyte beyond a single cornerstone product toward a high-quality, growth-oriented portfolio across hematology, oncology and immunology.”

Looking ahead, Incyte’s guidance reflects a more cautious outlook, with management highlighting the sequencing and timing of regulatory approvals and product launches as critical factors. The company is prioritizing execution on upcoming launches for Jakafi XR, Opzelura in Europe, and povorcitinib, while also preparing for regulatory submissions and late-stage trial readouts. CFO Thomas Tray reaffirmed that, “Our pipeline is advancing with multiple catalysts ahead, and we’ve strengthened our leadership team to support the next phase of execution.”

Key Insights from Management’s Remarks

Management attributed the quarter’s strong revenue growth to robust demand for both legacy and new products, as well as progress in pipeline development and organizational changes intended to support future launches.

• Portfolio diversification underway: Incyte’s transition from reliance on Jakafi to a broader portfolio is gaining traction, with non-Jakafi products contributing a growing share of revenue. Management highlighted that products outside Jakafi grew 63% year-over-year, reflecting the impact of Opzelura, Niktimvo, Monjuvi, and Zynyz.
• Pipeline progress across franchises: Several late-stage clinical programs advanced, including the FDA acceptance of povorcitinib for hidradenitis suppurativa (HS) and positive Phase III results in nonsegmental vitiligo. Additionally, pivotal trials in hematology, such as the mutant CALR antibody (989) in essential thrombocythemia (ET), remain on track to start midyear.
• Jakafi franchise stability: Jakafi sales rose 7% year-over-year, with stable prescriber base and broad formulary coverage. Management is preparing for the Jakafi XR launch and expects it to serve both as a new revenue stream and a bridge for the franchise.
• International expansion: Opzelura saw robust growth in international markets, particularly in vitiligo, and regulatory reviews are underway for additional indications in Europe. These developments are expected to enhance geographic diversification.
• Leadership restructuring: The appointment of new executives, including Suky Upadhyay as CFO and Mohamed Issa as Head of U.S. Commercial, is intended to streamline operations and prepare the organization for multiple upcoming launches, with a focus on analytics, market access, and patient services.

Drivers of Future Performance

Incyte’s outlook is shaped by the pace of regulatory approvals, the execution of new product launches, and the ability to scale its commercial infrastructure for expanded indications.

• Regulatory milestones and launches: Management expects four new product launches in the next year, including Jakafi XR, Opzelura for moderate atopic dermatitis in Europe, Monjuvi in first-line DLBCL, and povorcitinib in HS. The timing and success of these launches will be critical for driving near-term growth and offsetting any plateau in Jakafi sales.
• Pipeline execution and trial results: Late-stage clinical readouts, such as those for mutant CALR antibody (989) in ET and MF, as well as pivotal data from the KRAS G12D inhibitor (734) in pancreatic cancer, are expected later this year. Positive outcomes could expand the addressable market and strengthen Incyte’s position in hematology and oncology.
• Commercial infrastructure readiness: Recent organizational changes are aimed at supporting a more integrated and launch-ready commercial operation. Management cautioned that the sequencing of launches and speed of regulatory decisions could impact the revenue mix and margin profile, especially given the company’s goal of having its immunology and inflammation portfolio contribute one-third of revenue by 2030.

Catalysts in Upcoming Quarters

In the coming quarters, our team will monitor (1) regulatory decisions and launch execution for Jakafi XR, Opzelura in Europe, Monjuvi in first-line DLBCL, and povorcitinib in HS; (2) key late-stage clinical trial readouts in hematology and oncology, particularly for the mutant CALR antibody and KRAS G12D inhibitor; and (3) the impact of recent leadership changes and commercial integration efforts on launch effectiveness. Success in these areas could determine whether Incyte achieves its near- and long-term growth ambitions.

Incyte currently trades at $97.12, up from $95.72 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.